Arena Pharmaceuticals Inc (ARNA)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
CEO:
Amit D. Munshi
Employees:
194
6154 NANCY RIDGE DRIVE, SAN DIEGO, CA 92121
858-453-7200

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Arena Pharmaceuticals, Inc. focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Crohn's disease, alopecia areata, and atopic dermatitis. Olorinab (APD371) and APD418 (APD418) are in Phase I clinical trials for acute heart failure.

Data derived from most recent annual or quarterly report
Market Cap 6.165 Billion Shares Outstanding61.659 Million Avg 30-day Volume 1.677 Million
P/E Ratio5.8848 Dividend Yield0.0 EPS-10.14
Price to Revenue2.9117 Debt to Equity0.0426 EBITDA483.412 Million
Price to Book Value2.1915 Operating Margin59.862 Enterprise Value1.283 Billion
Current Ratio16.9 EPS Growth13.206 Quick Ratio16.447
1 Yr BETA 0.2482 52-week High/Low 100.0 / 45.5 Profit Margin49.2981
Operating Cash Flow Growth530.138 Altman Z-Score15.1917 Free Cash Flow to Firm 498.941 Million
View SEC Filings from ARNA instead.

View recent insider trading info

Arena Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ARNA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ARNA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-03-11 by NOVA TINA SUSAN
  • 4: filed on 2022-03-11 by FETZER OLIVER
  • 4: filed on 2022-03-11 by GALLAHUE KIERAN
  • 4: filed on 2022-03-11 by KNOBIL KATHARINE
  • 4: filed on 2022-03-11 by JARRETT JENNIFER
  • 4: filed on 2022-03-11 by NEIL GARRY ARTHUR
  • 4: filed on 2022-03-11 by SCHOCH STEVEN J
  • 4: filed on 2022-03-11 by DALLAS JAYSON DONALD ALEXANDER
  • 4: filed on 2022-03-11 by OUZREN NAWAL
  • 4: filed on 2022-03-11 by MANION DOUGLAS J.

    • Events (8k)

  • 8-K: filed on 2022-03-11:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-10:
    Item 8.01: Other Events
  • 8-K: filed on 2022-02-23:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-07:
    Item 8.01: Other Events
  • 8-K: filed on 2022-01-07:
    Item 8.01: Other Events
  • 8-K: filed on 2021-12-13:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2021-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FETZER OLIVER

    • Director
    		 0 2022-03-11 0

    NOVA TINA SUSAN

    • Director
    		 0 2022-03-11 0

    GALLAHUE KIERAN

    • Director
    		 0 2022-03-11 0

    NEIL GARRY ARTHUR

    • Director
    		 0 2022-03-11 0

    MUNSHI AMIT PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2022-03-11 0

    STELZER LAURIE EVP & CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2022-03-11 0

    DALLAS JAYSON DONALD ALEXANDER

    • Director
    		 0 2022-03-11 0

    AURENTZ VINCENT EXECUTIVE VP AND CBO

    • Officer
    		 0 2022-03-11 0

    JARRETT JENNIFER

    • Director
    		 0 2022-03-11 0

    KNOBIL KATHARINE

    • Director
    		 0 2022-03-11 0

    LISICKI ROBERT EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2022-03-11 0

    SCHMIDT JOAN EVP, GENERAL COUNSEL & SEC

    • Officer
    		 0 2022-03-11 0

    OUZREN NAWAL

    • Director
    		 0 2022-03-11 0

    SCHOCH STEVEN J

    • Director
    		 0 2022-03-11 0

    MANION DOUGLAS J. EVP RESEARCH & DEVELOPMENT

    • Officer
    		 0 2022-03-11 0

    CABELL CHRISTOPHER EVP, HEAD OF R&D, AND CMO

    • Officer
    		 6,401 2020-11-25 0

    SONI MANMEET SINGH

    • Director
    		 5,902 2020-06-17 0

    KLASSEN PRESTON EVP AND CMO

    • Officer
    		 0 2020-03-01 0

    LIND KEVIN ROBERT EXECUTIVE VP AND CFO

    • Officer
    		 0 2020-03-01 0

    SPECTOR STEVEN W EVP, GENERAL COUNSEL & SEC

    • Officer
    		 17,437 2020-02-27 0

    WOODS RANDALL E

    • Director
    		 14,230 2019-11-12 0

    SCHNEIDER PHILLIP M

    • Director
    		 0 2017-06-13 0

    BICE SCOTT H

    • Director
    		 0 2017-06-13 0

    WHITE CHRISTINE ANNA

    • Director
    		 0 2017-06-13 0

    HIXSON HARRY F JR

    • Director
    		 0 2016-06-13 0

    BELCHER DONALD D

    • Director
    		 0 2016-06-13 0

    BEHAN DOMINIC P EVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    • Director
    		 0 2016-03-02 0

    SHANAHAN WILLIAM R JR SVP & CHIEF MEDICAL OFFICER

    • Officer
    		 0 2016-03-02 0

    BIELASZ JENNIFER KATHLEEN VP, FINANCE AND ACCOUNTING

    • Officer
    		 0 2016-03-02 0

    AUDET CRAIG MICHAEL SVP, OPN & HEAD GLOB REG AFRS

    • Officer
    		 0 2016-03-02 0

    MEZZINO MAURICE JAMES SVP, CORPORATE DEVELOPMENT

    • Officer
    		 0 2016-03-02 0

    LIEF JACK PRESIDENT AND CEO

    • Officer
    • Director
    		 622,189 2015-03-03 0

    HOFFMAN ROBERT SVP, FINANCE AND CFO

    • Officer
    		 58,074 2014-12-15 0

    AJIT-SIMH K A SR. VP, QUALITY & REG COMPL

    • Officer
    		 0 2011-03-15 0

    LAFORCE JAMES

    • Director
    		 0 2010-03-17 0

    FLYNN JAMES E

    DEERFIELD CAPITAL LP

    DEERFIELD MANAGEMENT CO /NY

    DEERFIELD INTERNATIONAL LTD

    DEERFIELD PARTNERS, LP

    • 10% Owner
    		 5,100,643 2007-10-19 0

    SCOTTI LOUIS J VP, MARKETING AND BUSINESS DEV

    • Officer
    		 27,324 2007-09-26 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 22:15:03 UTC -0.2504 0.3204 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 21:45:03 UTC -0.5492 0.6192 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 21:15:03 UTC -0.5492 0.6192 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 20:45:03 UTC -0.5492 0.6192 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 20:15:03 UTC -0.5492 0.6192 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 19:45:03 UTC -0.5492 0.6192 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 19:15:04 UTC -0.5492 0.6192 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 18:45:03 UTC -0.5492 0.6192 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 18:15:03 UTC -0.5492 0.6192 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 17:45:03 UTC -0.5492 0.6192 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 17:15:04 UTC -0.5492 0.6192 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 16:45:03 UTC -0.2504 0.3204 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 16:15:03 UTC -0.2504 0.3204 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 15:45:03 UTC -0.2504 0.3204 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 15:15:03 UTC -0.2504 0.3204 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 14:45:03 UTC -0.2504 0.3204 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 14:15:03 UTC -0.2504 0.3204 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 13:45:03 UTC -0.2504 0.3204 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 13:15:03 UTC -0.2504 0.3204 1800000
    ARENA PHARMACEUTICALS INC ARNA 2022-03-11 12:45:03 UTC -0.2504 0.3204 1800000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Trust for Professional Managers- Convergence Market Neutral Fund ARNA -991.0 shares, $-69191.62 2020-08-31 N-PORT
    FundVantage Trust- Gotham Defensive Long Fund ARNA -58.0 shares, $-2436.0 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund ARNA -91.0 shares, $-3822.0 2020-03-31 N-PORT
    RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund ARNA -1649.0 shares, $-122421.76 2021-01-31 N-PORT
    Trust for Professional Managers- Convergence Long/Short Equity Fund ARNA -530.0 shares, $-28879.7 2021-11-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments